Hvordan Teva præger næste kapitel af neurovidenskaben

What is your work in the field of neuroscience and at Teva? Dieter: I've been working in neuroscience now for 30 years as a medical doctor and as a professional in medical affairs. There's one thing I really learned about neurological conditions. It destroys people's life, the lives as they have known it comes to an end so I'm driven very much by bridging the gap between clinical research and medical practice. After all, I think it’s the coolest thing I could ever do to help somebody else, to give somebody hope. Does Teva have a strong heritage in neuroscience? Dieter: Teva is not a newcomer to neuroscience. We have a very strong footprint in neuroscience, and it started nearly 30 years ago in multiple sclerosis. So we now have medications in migraine and headache, movement disorders but also lately in schizophrenia and let’s not forget, we also have a very broad generics portfolio in neuroscience, that makes medication accessible all over the globe to people who need it. Is Teva also investigating new technologies? Dieter: We have to use the modern technology. We have to combine it with the tried and tested in order to speed up the development of medications. Patients can't wait ten plus years for a new medication to come along so we are using AI for different purposes to enhance diagnosis, but also to speed up the clinical development program. Has Teva prioritized neuroscience due to its high unmet patient need? Dieter: Neuroscience has got a very high unmet medical need. There's great suffering, to illustrate that, one third of the global population suffers from a condition which is under the umbrella of neuroscience. That's not necessary and we can do something about it and Teva actually does do something about it.